tbuckley/cabot-search huggingface dataset:
WASHINGTON NEWS
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Alcoholism
Authors: Robert L. Martensen
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Screening Mammography-Reply
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Procalcitonin, A Donor-Specific Predictor of Early Graft Failure-Related Mortality After Heart Transplantation
Authors: Frank D. Wagner, Britta Jonitz, Evgenij V. Potapov, Naser Qedra, Karl Wegscheider, Klaus Abraham, Ekaterina A. Ivanitskaia, Matthias Loebe, Roland Hetzer
Journal: Circulation (2001)

Background To date, donor-specific markers to predict outcome after heart transplantation (HTx) are unknown. Increased procalcitonin (PCT) levels have been found in infectious inflammation with systemic reactions and/or poor organ perfusion but have not been studied in heart donors. We evaluated PCT as a predictor of early graft failure-related mortality after HTx. Methods and Results PCT and C-reactive protein (CRP) serum concentrations were measured in samples collected immediately before pericardium opening from 81 consecutive brain-dead multiple-organ donors. Donors for high-urgency-status recipients (n=2) were excluded from analysis. The remaining donors were retrospectively divided into 2 groups: donors for recipients who died within 30 days after HTx, after an early graft failure (group II, n=8), and all other donors (group I, n=71). No differences in donor and recipient demographic characteristics were found between groups. Areas under the receiver operating characteristic curves for graft failure-related mortality were 0.71 for PCT and 0.64 for CRP. A PCT value &gt;2 ng/mL as a predictor of graft failure-related mortality had a specificity of 95.8% and sensitivity of 50.0%. The odds ratio for graft failure-related mortality for recipients of hearts from donors with PCT levels &gt;2 ng/mL was 22.7 (unadjusted, 95% CI 3.7 to 137.8, P =0.0007) and 43.8 (after adjustment for prespecified potential confounders, 95% CI 1.4 to 1361.0, P =0.031). Conclusions A PCT level &gt;2 ng/mL in a cardiac donor at the time of explantation appears to predict early graft failure-related mortality.
Sherbet
Authors: Jerald Winakur
Journal: Annals of Internal Medicine (2005)

Ad Libitum15 February 2005SherbetJerald Winakur, MDJerald Winakur, MDFrom Comfort, TX 78013.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-142-4-200502150-00013 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail A few weeks after her dischargeafter the legions of modernmiracles mobilizedunder my commandmet her dauntless infirmityI finally retreatedshe waits now in this way stationwhere I comeno longer in whiteshe is wearya heavilybreathing shadowstaring out the windowa tray of clottedfood perched nearbyI ask how she feelsbut she does not answerthe raspberry sherbet is meltingyet it is my only ammunitiona plastic spoon my only weaponI bring it to her parched lipsand she eats for meI say isn't the sky so bluetoday the clouds so whiteurging ... Author, Article, and Disclosure InformationAffiliations: From Comfort, TX 78013.Current Author Address: Jerald Winakur, MD, PO Box 128, Comfort, TX 78013. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 February 2005Volume 142, Issue 4Page: 301KeywordsBreathingEatingFoodThorax ePublished: 15 February 2005 Issue Published: 15 February 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.Loading ...
Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma
Authors: R. J. Motzer
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To define outcome data and prognostic criteria for patients with metastatic renal cell carcinoma (RCC) treated with interferon-alfa as initial systemic therapy. The data can be applied to design and interpretation of clinical trials of new agents and treatment programs against this refractory malignancy. PATIENTS AND METHODS: Four hundred sixty-three patients with advanced RCC administered interferon-α as first-line systemic therapy on six prospective clinical trials were the subjects of this retrospective analysis. Three risk categories for predicting survival were identified on the basis of five pretreatment clinical features by a stratified Cox proportional hazards model. RESULTS: The median overall survival time was 13 months. The median time to progression was 4.7 months. Five variables were used as risk factors for short survival: low Karnofsky performance status, high lactate dehydrogenase, low serum hemoglobin, high corrected serum calcium, and time from initial RCC diagnosis to start of interferon-α therapy of less than one year. Each patient was assigned to one of three risk groups: those with zero risk factors (favorable risk), those with one or two (intermediate risk), and those with three or more (poor risk). The median time to death of patients deemed favorable risk was 30 months. Median survival time in the intermediate-risk group was 14 months. In contrast, the poor-risk group had a median survival time of 5 months. CONCLUSION: Progression-free and overall survival with interferon-α treatment can be compared with new therapies in phase II and III clinical investigations. The prognostic model is suitable for risk stratification of phase III trials using interferon-α as the comparative treatment arm.
J Français de Méd et Chir Thoraciques, Paris
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: R. W. CARLSON
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article BOOK REVIEWS Get access The Etiology of Cancer, CD-ROM, Version 1 Nadine Small , Norwood, Mass. : SilverPlatter Education, Inc. , 1993 . Institutional: $750; Individual:$245 (AMA members: $225) ROBERT W. CARLSON, M.D. ROBERT W. CARLSON, M.D. Stanford University Medical Center300 Pasteur Dr. Stanford, CA 94305 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 10, 18 May 1994, Pages 795–796, https://doi.org/10.1093/jnci/86.10.795-a Published: 18 May 1994
Miscellany.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An alanine-to-threonine substitution in protein 4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein 4.2NIPPON)
Authors: EE Bouhassira, RS Schwartz, Y Yawata, K Ata, A Kanzaki, JJ Qiu, RL Nagel, AC Rybicki
Journal: Blood (1992)
Correction: Is uterine growth retardation with normal umbilical artery blood flow a benign condition?
Journal: BMJ (1990)

nearly twice that of normotensive men (Mantel- Haenszel pooled estimate of odds ratio 1 79; 95% confidence interval 1 53 to 2 09).In treated hypertensive men the Mantel-Haenszel pooled estimate of odds ratio for the age adjusted relative risk was 2 63 (95% confidence interval 2 23 to 3 10).TABLE InV-Age adjlusted prevalence of histonr of kidney stones in relation to hypertensioni Age adjusted '3z0 with history of stones Normotensive subjects (n= 509) 14 Untreated hypertensive subjects (n= 118) 18 Treated hypertensive subjects (n=61) 33
JAMA 75 YEARS AGO
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies
Authors: Karsten Haug, Maike Warnstedt, Alexi K. Alekov, Thomas Sander, Alfredo Ramírez, Barbara Poser, Snezana Maljevic, Simon Hebeisen, Christian Kubisch, Johannes Rebstock, Steve Horvath, Kerstin Hallmann, Joern S. Dullinger, Birgit Rau, Fritz Haverkamp, Stefan Beyenburg, Herbert Schulz, Dieter Janz, Bernd Giese, Gerhard Müller-Newen, Peter Propping, Christian E. Elger, Christoph Fahlke, Holger Lerche, Armin Heils
Journal: Nature Genetics (2003)
Obituary Listing
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Arboviral Disease—United States, 1991
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1943: Highly specific tumor-targeting near-infrared persistent luminescence nanomaterials (ZGO and LGGO) for lung cancer bioimaging
Authors: Ming-Hsien Chan, Ru-Shi Liu, Michael Hsiao
Journal: Cancer Research (2019)

Abstract Lung cancer cells grow in-situ usually results in metastasis and is frequently recurrent after therapy. Moreover, treatment of lung cancer using surgery or chemotherapy is difficult to determine that all tumor tissue has been removed. ZnGa2O4/La3GaGe5O16 (ZGO and LGGO) persistent luminescence nanomaterials (PLNs) which are based on the biological characteristics of metastatic or remaining lung cancer cells, to promote the clinical application of these nanomaterials for long-term specific tracking. A silica shell-assisted synthetic route for mono-disperse, near infrared-PLNs, will be developed and applied in the, in vitro cell model and in vivo mouse model. The Cr3+-doped PLNs can hold the emitted light longer than several hours. These NIR-PLNs will absorb the energy of UV or X-ray light first and retain fluorescence emission. Moreover, we will identify the specific aptamer, MAGE-A3, and modify the PLN’s design accordingly, to increase the ability of cancer targeting. These targeted molecules can track the metastatic cell with specific binding. The advancement of nanoscale techniques in lung cancer is an urgent need. Hence, this research will deliver a credible diagnostic strategy and a novel method for therapeutic administration. To evaluate the luminescent effect in vitro and in vivo of NIR-PLNs, repeated in vivo NIR persistent luminescence images of a mouse after intravenous injection (I.V.) and intratracheal injection (I.T.) of NIR-PLNs. After the NIR-PLNs is irradiated with UV light for 120 seconds in vitro, the particles are entering in the mouse by I.V. and I.T. It is seen that NIR persistent luminescence signal could be repeatedly observed over the mouse’s lung tumor tissue for more than 6 hours. Interestingly, no significant NIR luminescence signal can be observed in the other parts of the mice. The major task is, providing a potential strategy for diagnostic in lung cancer. The current diagnostic approach does not easily distinguish the metastatic and remaining tumor cells. Moreover, we anticipate that our designed nanoplatform or accessed procedure could be applied to other types of materials or cancers, leading NIR-PLNs nanomaterials to the exploration of gene-scale research. Citation Format: Ming-Hsien Chan, Ru-Shi Liu, Michael Hsiao. Highly specific tumor-targeting near-infrared persistent luminescence nanomaterials (ZGO and LGGO) for lung cancer bioimaging [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1943.
Computerized monitoring of cardiac output by thermal dilution
Authors: R. J. Ellis
Journal: JAMA (1972)

Determinations of cardiac output are essential to the management of patients in cardiogenic shock and those undergoing open-heart surgery. Because of this growing demand for better methods, the thermal dilution technique has been developed for clinical use. Saline at room temperature is injected via the subclavian vein, and the temperature change is recorded by the thermistor in the pulmonary artery and cardiac output is read off immediately. Cardiac outputs can be determined as frequently as every 20 seconds, using saline injections of 7 to 10 cc for each determination. Consistency is in the range of less than 100-cc differences between sequential determinations. Many seriously ill patients have had cardiac outputs determined with this method. This experience has demonstrated that the thermal dilution technique is very reliable, and that it can be used in acute clinical situations with ease and excellent reproducibility.
Masthead: (Adv. Healthcare Mater. 22/2017)
Journal: Advanced Healthcare Materials (2017)

Citizenship: Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups.Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts.
NCCN NewsNew NCCN Imaging Appropriate Use Criteria Published for 8 Cancer TypesNCCN Imaging Appropriate Use Criteria to be Integrated into New Century Health's Oncology Clinical Decision Support PlatformNCCN Awards 3 Grants to Investigators to Study Bavituximab in Combination with Other Therapeutic Strategies in Various CancersNCCN Imaging Appropriate Use Criteria to be Integrated into MedCurrent's OrderWise PlatformCall for Abstracts! NCCN to Hold General Poster Session at 22nd Annual …
Journal: Journal of the National Comprehensive Cancer Network (2016)

New NCCN Imaging Appropriate Use Criteria Published for 8 Cancer Types NCCN, a Centers for Medicare & Medicaid Services (CMS)-approved provider-led entity for imaging appropriate use criteria (AUC), continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC) for 8 new cancer types.Launched in June 2016, NCCN Imaging AUC currently are available for 20 cancer types; the new NCCN Imaging AUC are available for: NCCN Imaging Appropriate Use Criteria to be Integrated into New Century Health's Oncology Clinical Decision Support PlatformNCCN is extending its collaboration with New Century Health to integrate the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC) into New Century Health's value-based clinical decision support platform.This will provide expanded access to imaging recommendations as derived from the NCCN Guidelines.